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Condensation:  
MR images depict a marked response to Ulipristale Acetate in a woman with large uterine 
fibroids,  and demonstrate no significant regrowth during pregnancy or 12 weeks postpartum. 
 
Short Title: UPA non-surgical fibroids control 
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Case note: A 39-year-old woman under our care for five years for multiple uterine fibroids 
presented requesting a review of her condition with a view to attempting pregnancy. Previous 
treatment included laparotomic myomectomy in 2006, GnRH agonist therapy (monthly 
leuprolide acetate injections in the PEARL II study1) in 2008, and hysteroscopic 
myomectomy in 2009, and had been asymptomatic on desogestrel treatment for 1 year. On 
clinical examination, uterine volume was equivalent to 20 weeks' gestation and magnetic 
resonance imaging (MRI) revealed multiple, disseminated, diffuse myomatosis (Figure A). 
Treatment was initiated with 5 mg oral ulipristal acetate (UPA) daily. MRI evaluation showed 
a significant decrease in fibroid volume after 3 months, continuing after 6 months (Figures B, 
C). Without surgery, the patient proceeded with in vitro fertilization for andrologic concern 
and age.  Pregnancy was confirmed following her first embryo transfer, 11 months after 
beginning and 3.5 months after ending UPA treatment. No significant fibroid regrowth was 
noted at MRI performed during pregnancy (Figures D, E). Because of previous laparotomy 
with myomectomy, cesarean section was planned and a healthy baby was delivered at 
39 weeks. Follow-up MRI 12 weeks after delivery showed sustained regression of the 
myomas, both in number and size, also due to  'natural' remodeling after pregnancy2 (Figure 
F). The patient remains asymptomatic one year post-delivery.  
Comment: This MRI-based analysis of UPA treatment for diffuse uterine myomatosis reveals 
an unprecedented level of effectiveness, sustained even throughout the subsequent pregnancy. 
However, fibroid response to UPA in terms of volume reduction is very unpredictable3. 
Courtoy et al. conducted immunohistochemistry, microarrays and histology studies on 
surgical specimens and described a multifactorial mechanism of action4: UPA increased 
apoptosis of myoma cells, but only at the beginning of treatment, by a pathway independent 
of the caspase. After long-term treatment with UPA, modification of the extra-cellular matrix 
(ECM) was significant compared to the untreated group, with an increase in matrix 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
metalloproteinase 2 (MMP-2) levels. Hence, in patients showing such a marked response to 
UPA treatment, it is possible that pregnancy could continue to modify the ECM by uterine 
growth. The remaining fibroid cells may have been selected by primary UPA-mediated 
apoptosis resulting in a population of cells less sensitive to hormonal stimulation, due to 
modification of  progesterone receptor expression, as shown for other selective progesterone 
receptor modulators5. 
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Figure: MRI images showing regression of uterine fibroids during UPA treatment and 
subsequent pregnancy 
Multiple large myomas (dark ovals) and a distorted and reduced-capacity uterine cavity (light area) 
were visible before treatment (A). Subsequent MRIs showed successive improvements after 3 months 
(B) and 6 months (C) of UPA; with no significant regrowth during early pregnancy (D, 13 weeks’ 
gestation). Further shrinkage was observed in the third trimester (E, 32 weeks’ gestation), with 
disappearance of most fibroids by 12 weeks after delivery (F). 
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